Overview: Articles by Peter Lehmann & further authors     Homepage of Peter Lehmann Publishing

Peter Lehmann

Achievement of Full Human Rights and Appropriate Support for People with Emotional Distress and Psychiatric Diagnoses

Mode of action, risks & damages of psychiatric drugs

• Lehmann, Peter: "World list of prescribed psychotropic drugs' active ingredients (generic names), trade names and test codes". Occasionally updated file. Online resource https://www.peter-lehmann-publishing.com/info/psychodrugs.htm

• Lehmann, Peter (2025): "For and against dependence on antidepressants and neuroleptics: Who benefits?" (pp. 81-133). In: Peter Lehmann & Craig Newnes (eds.): "Withdrawal from prescribed psychotropic drugs". Updated e-book edition. Berlin & Lancaster: Peter Lehmann Publishing. Print edition. Lancaster: Egalitarian Publishing 2023, pp. 45-76]

• Lehmann, Peter (August 27, 2016): "Responding to the catastrophic reduction of psychiatric patients' life expectancy". PowerPoint presentation / keynote lecture to the conference "Rights Under Siege: Fighting Back", run by the National Association for Rights Protection and Advocacy. Phoenix, Arizona. Online resource https://peter-lehmann-publishing.com/articles/lehmann/ppt/lehmann_mortality-phoenix.pdf

• Lehmann, Peter (2013): "Early warning signs of chronic or lethal diseases due to the administration of neuroleptics". In: Journal of Critical Psychology, Counselling and Psychotherapy, Vol. 13, No. 1, pp. 23-29. Online resource https://www.peter-lehmann-publishing.com/articles/lehmann/pdf/warningsigns-jcpcp.pdf

• Lehmann, Peter (2013): "How relevant is Franco Basaglia currently? Psychiatrists, psychotherapists and the reduced life expectancy of psychiatric patients". Abstract. In: Psychotherapie-Wissenschaft, Vol. 3. (2013), No. 2, p. 79. Online resource https://www.psychotherapie-wissenschaft.info/index.php/psywis/article/view/169/229

• Lehmann, Peter (July 7, 2009): "The spirit of what has not been said". PowerPoint response to John Sadler's lecture "Personal and community capacities: Philosophical conundrums", presented to the Summer Colloquium 2009: "Interpersonal awareness and mental health". University of Central Lancashire, Faculty of Health – Centre for Ethnicity and Health, Institute for Philosophy, Diversity and Mental Health, Preston, England. Online resource https://www.peter-lehmann-publishing.com/articles/lehmann/ppt/spirit-preston2009-ppt.pdf

• Lehmann, Peter (2005): "All about PSY DREAM: Psychiatric drug registration, evaluation and all-inclusive monitoring". In: Epidemiologia e psichiatria sociale, Vol. 14, No. 1, pp. 15-21. Online resource https://www.peter-lehmann-publishing.com/articles/lehmann/epidemiologia_2005.htm

• Lehmann, Peter (2004): "PSY DREAM: Psychiatric drug registration, evaluation and all-inclusive monitoring". In: Journal of Critical Psychology, Counselling and Psychotherapy, Vol. 4, No. 4, pp. 233-241. Online resource https://www.peter-lehmann-publishing.com/articles/lehmann/pdf/psy-dream_jcpcp.pdf

• Lehmann, Peter (1997): "For and against psychotropic drugs: Proposal as position-paper for the European Network of (ex-) Users and Survivors of Psychiatry" (pp. 18-20). In: European Network of (ex-) Users and Survivors of Psychiatry: "Third Conference – Reading, England, January 3-6, 1997". Utrecht: ENUSP.Online resource https://www.peter-lehmann-publishing.com/articles/lehmann/for_against.htm

• Lehmann, Peter (1994): "The medical model, diagnostics and treatment methods" (pp. 28-30). In: European Network of Users and Ex-Users in Mental Health (eds.): "The second European conference of users and ex-users in mental health – The international people's college". Amsterdam: European Network of Users and Ex-Users in Mental Health. Online resource https://www.peter-lehmann-publishing.com/articles/lehmann/pdf/medical-modell.pdf

Articles by further authors

• Aderhold, Volkmar: Neuroleptics – Effects, risks, education and treatment contexts. Unpublished manuscript, January 2007

• Aderhold, Volkmar: Minimum dosage and monitoring of neuroleptics. In: Journal of Critical Psychology, Counselling and Psychotherapy, Vol. 20 (2020), No. 4 (Special edition: "Withdrawal from prescribed drugs", edited by Peter Lehmann), pp. 31-50

• Breggin, Peter: $ 6.7 million awarded in Risperdal tardive dyskinesia case. Internet-publication, 2000

• Fleming, Sean: The failure to inform psychiatric "patients" of the dangers of neuroleptic drugs in Ireland. Unpublished manuscript from 2005

• Frank, Leonard Roy: Interview about so-called atypical neuroleptics like Zyprexa, Risperdal, Seroquel on YouTube

• Gottstein, Jim in interview #192 with the World Pirate Network Podcast Network on the Zyprexa Papers

• Gottstein, Jim & PsychRights^© – Law Project for Psychiatric Rights: Case XX and the Zyprexa papers scandal

• Hough, Jennifer: Psychiatric patients unaware of prescription drug risks. In: Irish Examiner, November 17, 2011

• Landesnetzwerk Selbsthilfe seelische Gesundheit Rheinland-Pfalz e.V. – NetzG-RLP, Volkmar Aderhold, Brigitte Anderl-Doliwa, Anke Brockhaus-Dumke, Silvia Claus, Stefan Elsner, Andreas Konrad, Peter Lehmann, Petra Loerzer, Frank Rettweiler & Franz-Josef Wagner (2018): "Antipsychotics information brochure" (pp. 13-16). In: NetzG-RLP (eds.): "Aufklärungsbögen Antipsychotika in deutscher, englischer, französischer, polnischer, spanischer, rumänischer, serbokroatischer, türkischer, russischer und arabischer Sprache". Trier: NetzG-RLP. Online resource https://antipsychiatrieverlag.de/artikel/gesundheit/pdf/aufklaerung-nl-inter.pdf

• Martensson, Lars: Should neuroleptice be banned? In: The Voiceless Movement / Les Sans-Voix (eds.): Deprived of our humanity – The case against neuroleptic drugs, Geneva: Association Ecrivains, Poètes & Cie. 1998, pp. 97-148 (plus attendum and publication history)

• Penney, Darby: Lack of information about risks and options: Innovative ways to overcome this world-wide ethical problem in psychiatry. Powerpoint presentation within the symposium Responding to the Frightening Reduction of Psychiatric Patients' Life Expectancy, led by Peter Lehmann / Salam Gómez, to the WPA XVII. World Congress of Psychiatry ("Psychiatry of the 21st Century: Context, Controversies and Commitment"), Berlin, October 11, 2017

• Stastny, Peter: Taking charge of psychotropic drugs. In: Disability Studies Quarterly, Vol. 13 (1993), No. 2, pp. 32-38

• Whitaker, Robert: Do antipsychotics reduce the risk of relapse? In: Journal of Critical Psychology, Counselling and Psychotherapy, Vol. 20 (2020), No. 4 (Special edition: "Withdrawal from prescribed drugs", edited by Peter Lehmann), pp. 87-97. And in: Peter Lehmann & Craig Newnes (eds.): Withdrawal from prescribed psychotropic drugs, updated e-book edition, Berlin & Lancaster: Peter Lehmann Publishing 2025. Print edition, Lancaster: Egalitarian Publishing 2023, pp. pp. 145-166

• Whitaker, Robert: Psychiatry Defends Its Antipsychotics. A Case Study of Institutional Corruption MIA Report: Lieberman says critics of the drugs "create mischief for their own nefarious purposes." On MadinAmerica, May 21, 2017

Last updated on December 8, 2025